Table 3. Synergistic increase of CRE-mediated luciferase activity in PHN.

Treatment	% increase over control
DADLE (0.01 nM)	8 ± 6
Met (0.02 nM)	5 ± 8
NPA (0.5 nM)	3 ± 9
EtOH (25 mM)	4 ± 7
NPA + DADLE	46 ± 9*
NPA + DADLE + BW	5 ± 4
NPA + DADLE + Rp-cAMPS	1 ± 7
NPA + DADLE + PTX	9 ± 5
NPA + DADLE + QEHA	3 ± 5
NPA + Met	42 ± 8*
NPA + Met + BW	–7 ± 3
NPA + Met + Rp-cAMPS	8 ± 4
NPA + Met + PTX	1 ± 5
NPA + Met + QEHA	–5 ± 4
EtOH + DADLE	38 ± 8*
EtOH + DADLE + BW	5 ± 2
EtOH + DADLE + Rp-cAMPS	7 ± 9
EtOH + DADLE + PTX	–4 ± 8
EtOH + DADLE + QEHA	8 ± 7
EtOH + Met	43 ± 9*
EtOH + Met + BW	3 ± 4
EtOH + Met + Rp-cAMPS	9 ± 5
EtOH + Met + PTX	–3 ± 2
EtOH + Met + QEHA	4 ± 2
DADLE + Met	8 ± 8

^*P < 0.01 compared with control as in Table 1